Sunita Badola

  • Citations Per Year
Learn More
PURPOSE This planned exploratory analysis assessed the predictive nature of baseline circulating factors of the insulin-like growth factor (IGF) axis on the treatment effect of ganitumab (monoclonal(More)
PURPOSE Ganitumab is a fully human monoclonal antibody against type-1 insulin-like growth factor receptor (IGF1R). An open-label phase II study was conducted to evaluate the efficacy and safety of(More)
4041 Background: GAN and conatumumab (CON) are investigational, fully human, monoclonal antibodies against type 1 insulin-like growth factor receptor (IGF1R) and death receptor 5, respectively. A(More)